ADP receptors of platelets and their inhibition

Thrombosis and Haemostasis

Volumn 86, Issue 1, 2001, Pages 222-232

  Gachet, C ^a  

^a INSERM   (France)

Author keywords

ADP; Antiplatelet drugs; P2 receptors; Pharmacology; Platelets; Thrombosis

Indexed keywords

2' DEOXY 6 N METHYLADENOSINE 3',5' BISPHOSPHATE; A2P5P; A3P5P; A3P5PS; ADENOSINE DERIVATIVE; ADENOSINE DIPHOSPHATE; ADENOSINE RECEPTOR; ADENOSINE TRIPHOSPHATE DERIVATIVE; ADENYLATE CYCLASE; ANTICOAGULANT AGENT; AR C 66096MX; AR C 67085MX; AR C 69931MX; ARC 66096MX; ARC 67085MX; ARC 69931MX; ASP5P; C 1330 7; CLOPIDOGREL; G PROTEIN COUPLED RECEPTOR; MRS 2279; N6 METHYL 2' DEOXYADENOSINE 3',5' DIPHOSPHATE; PRASUGREL; PURINE ANTAGONIST; PURINE P2 RECEPTOR; PURINE P2X RECEPTOR; PURINE P2Y RECEPTOR; TICLOPIDINE; UNCLASSIFIED DRUG;

CALCIUM MOBILIZATION; CONFERENCE PAPER; DRUG INHIBITION; DRUG TARGETING; ENZYME DEFICIENCY; EXPERIMENTAL MODEL; HEMOLYSIS; HEMOSTASIS; HUMAN; KNOCKOUT MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BINDING; STRUCTURE ANALYSIS; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOSIS;

EID: 0034911702     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1616220     Document Type: Conference Paper

References (133)

1. The adhesiveness of human blood platelets in vitro
2. Adenosine diphosphate in red cells as a factor in the adhesiveness of human blood platelets
3. Macroscopic studies of platelet aggregation: Nature of an aggregating factor in red blood cells and platelets
4. Aggregation of blood platelets by adenosine diphosphate and its reversal
5. Adenosine diphosphate as a mediator of platelet aggregation in vivo: An editorial point of view
6. Agonists and receptors: Adenosine diphosphate
7. ADP plays a key role in thrombogenesis in rats
8. Broad spectrum anti-platelet activity of ticlopidine and PCR 4099 involves the suppression of the effects of released ADP
9. Pharmacology of ticlopidine: A review
10. ADP receptors on platelets
11. ADP receptors and clinical bleeding disorders
12. Adenine nucleotides in blood platelets
13. Inherited abnormalities of platelet granules and signal transduction
14. Pharmacology of ticlopidine and clopidogrel
15. Pharmacology of AR-C69931MX and related compounds: From pharmacological tools to clinical trials
16. Effect of ADP utilizing enzymes on the arterial bleeding time in rats and rabbits
17. Targeted disruption of cd39/diphosphohydrolase results in disordered hemostasis and thromboregulation
18. Human ecto-ADPase/CD39: Thromboregulation via a novel pathway
19. Hereditary defect of the platelet ADP receptor(s)
20. Congenital defects of ADP receptors on platelets
21. Receptors for purines and pyrimidines
22. Molecular mechanisms of platelet activation
23. Factors responsible for ADP-induced release reaction of human platelets
24. 2+ in the suspending medium on the responses of human and rabbit platelets to aggregating agents
25. ADP is a potent inhibitor of human platelet plasma membrane adenylate cyclase
26. Inhibition of adenylate cyclase by ADP
27. Kinetic differences between thrombin induced and ADP induced calcium influx and release from internal stores in fura-2 loaded human platelets
28. Rapid ADP evoked currents in human platelets recorded with the nystatin permeabilized patch technique
29. Defective platelet activation in Gαq-deficient mice
30. Human platelet signaling defect characterized by impaired production of inositol-1,4,5-triphosphate and phosphatidic acid and diminished pleckstrin phosphorylation: Evidence for defective phospholipase C activation
31. Platelet signal transduction defect with Gα subunit dysfunction and diminished Gαq in a patient with abnormal platelet responses
32. Interactions of the pharmacological receptors of blood platelets with adenylate cyclase
33. ADP receptor induced activation of guanine nucleotide binding proteins in human platelet membranes
34. 2 proteins
35. Epinephrine potentiates human platelet activation but is not aggregating agent
36. Stromal cell-derived factor-1 and macrophage-derived chemokine: 2 chemokinase that activates platelets
37. Functional expression of CCR1, CCR3, CCR4, and CXCR4 chemokine receptors on human platelets
38. A key role of adenosine diphosphate in the irresversible platelet aggregation induced by the PAR1-activating peptide through the late activation of phosphoinositide-3-kinase
39. Released adenosine diphosphate stabilizes thrombin-induced human platelet aggregates
40. Lack of stability of aggregates after thrombin-induced reaggregation of thrombin-degranulated platelets
41. Thrombin-receptor agonist peptides, in contrast to thrombin itself, are not full agonists for activation and signal transduction in human platelets in the absence of platelet-derived secondary mediators
42. Adenosine diphosphate (ADP) and ADP receptor play a major role in platelet activation/aggregation induced by sera from heparin-induced thrombocytopenia patients
43. FcgammaRIIA requires a Gi-dependent pathway for an efficient stimulation of phosphoinositide 3-kinase, calcium mobilization, and platelet aggregation
44. Evidence for cross-talk between GPVI and Gi coupled receptors during collagen-induced platelet aggregation
45. ADP: An important cofactor of PI 3-kinase activation in human blood platelets
46. The effects of ATP on platelets: Evidence against the central role of released ADP in primary aggregation
47. Pharmacology of the platelet ADP receptor: Agonists and antagonists
48. Extracellular ATP: Effects, sources and fate
49. Cloning and functional expression of a brain G-protein-coupled ATP receptor
50. 1 purinoceptor
51. 1 purinoceptor
52. 1 receptor is an ADP receptor antagonized by ATP and expressed in platelets and megakaryoblastic cells
53. 1 receptors: Similarities with the platelet ADP receptor
54. 1 receptor mediates ADP-induced intracellular calcium mobilization and shape change in platelets
55. 1 purinoceptor in ADP-induced platelet activation
56. 1 receptor is necessary for ADP-induced platelet aggregation
57. Molecular basis for ADP-induced platelet activation. I. Evidence for three distinct ADP receptors on human platelets
58. Ligand specificity and ticlopidine effects distinguish three human platelet ADP receptors
59. 1-receptors in human platelets which are pharmacologically distinct from P2Y (ADP)-receptors
60. 1 receptor, necessary but not sufficient to support full ADP-induced platelet aggregation, is not the target of the drug clopidogrel
61. Evidence for two distinct G-protein-coupled ADP receptors mediating platelete activation
62. 1 receptor is normal in a patient presenting a severe deficiency of ADP-induced platelet aggregation
63. 1-deficient mice
64. 1 receptor null mice
65. 32P]diphosphate. An agonist and radioligand for the receptor that inhibits the accumulation of cyclic AMP in intact blood platelets
66. Identification of the platelet ADP receptor targeted by antithrombotic drugs
67. Evidence for two distinct G-protein-coupled ADP receptors mediating platelet activation
68. Identification and biological activity of the active metabolite of clopidogrel
69. ADP is the cognate ligand for the orphan G-protein coupled receptor SP1999
70. Evidence for the existence of two different ADP binding sites on rat platelets
71. 3H]-2 Methyl-thio-ADP to rat platelets. Effect of clopidogrel and ticlopidine
72. Purinoceptors on blood platelets: Further pharmacological and clinical evidence to suggest the presence of two ADP receptors
73. 33P]2MeS-ADP binding sites on platelets with secretion defect, normal granule stores and normal thromboxaneA2 production. Evidence that ADP potentiates platelet secretion independently of the formation of large platelet aggregates and thromboxane A2 production
74. 1 receptor antagonist
75. 1 not P2T purinoceptors in human platelets
76. 1 purinoceptors in human platelets and megakaryoblastic cell lines
77. 1 purinoceptor in human platelets. Molecular cloning and functional characterization after heterologous expression
78. 1 purinoceptor expressed on human platelets
79. 1 receptor, and adenosine triphosphate-gated cation channel, is expressed in human platelets but not in human blood leucocytes
80. 1 receptor
81. 1 receptors: Evidence for separate recetors stimulated by ATP and ADP on human platelets
82. Adenosine(5′) oligophospho-(5′) guanosines and guanosine(5′) oligophospho-(5′) guanosines in human platelets
83. Effects of diadenosine polyphosphates (Ap(n)As) and adenosine polyphosphoo guanosines (Ap(n)Gs) on rat mesenteric artery P2X receptor ion channels
84. The effects of diadenosine polyphosphates on the cardiovascular system
85. 1 receptor
86. 1 receptors by N6-methyl 2′-deoxyadenosine 3′, 5′-bisphosphate
87. 1 antagonists
88. Activity of novel adenine nucleotide derivatives as agonists and antagonists at recombinant rat P2X receptors
89. Synthesis, biological activity, and molecular modeling of ribose-modified deoxyadenosine bisphosphate analogues as P2Y(1) receptor ligands
90. 1 receptors antagonists
91. Antagonists of the platelet P2T receptor: A novel approach to antithrombotic therapy
92. 1
93. 1 activated platelet adenylate cyclase in rats and rabbits
94. ADP receptor induced activation of guanine nucleotide binding proteins in rat platelet membranes. An effect selectively blocked by the thienopyridine clopidogrel
95. Effect of clopidogrel treatment on ADP-induced phosphorylations in rat platelets
96. Specific impairment of human platelet P2Y(AC) ADP recetor-mediated signalling by the antiplatelet drug clopidogrel
97. Clopidogrel inhibits the binding of ADP analogues to the receptor mediating inhibition of platelet adenylate cyclase
98. The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP recetor antagonist properties
99. Identificaton of a new congenital defect of platelet function characterized by severe impairment of platelet responses to adenosine diphosphate
100. An inherited bleeding disorder linked to a defective interaction between ADP and its receptor on platelets
101. Abnormal tyrosine phosphorilation linked to a defective interaction between ADP and its receptor on platelets
102. 2 production and normal granule stores
103. 1 receptor leads to a mild bleeding disorder
104. 1 receptor due to deletion of a single amino acid residue
105. Coactivation of two different G protein-coupled receptors is essential for ADP-induced platelet aggregation
106. cAMP is not an important messenger for ADP-induced platelet aggregation
107. Role of intracellular signaling events in ADP-induced platelet aggregation
108. The central role of the P2T receptor in amplification of human platelet activation, aggregation, secretion and procoagulant activity
109. AC receptors in ADP-evoked calcium signaling in human platelets
110. 1 and P2cyc receptors
111. Activation of G12/G13 results in shape change and Rho/Rho-kinase-mediated myosin light chain phosphorylation in mouse platelets
112. Dichotomous regulation of myosin phosphorylation and shape change by Rho-kinase and calcium in intact human platelets
113. Platelet shape change is mediated by both calcium-dependent and -independent signaling pathways
114. ADP induces partial platelet aggregation without shape change and potentiates collagen-induced aggregation in the absence of Gαq
115. ADP-induced shape change: An investigation of the signalling pathways involved and their dependence on the method of platelet preparation
116. 1 receptor in transgenic mice
117. 2T receptors
118. Ultrastructural studies of platelet aggregates from human subjects receiving clopidogrel and from a patient with an inherited defect of an ADP-dependent pathway of platelet activation
119. 1 and P2cyc receptors in morphological changes during platelet aggregation
120. 1 receptors
121. 1 purinoceptors for platelet aggregation
122. 1 purinoceptors with α, β methylene ATP
123. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CARPIE)
124. Experimental thrombosis on a collagen coated arterioarterial shunt in rats: A pharmacological model to study antithrombotic agents inhibiting thrombin formation and platelet deposition
125. ADP plays an important role in mediating platelet aggregation and cyclic flow variations in vivo in stenosed and endothelium-injured canine coronary arteries
126. Clopidogrel is more effective than aspirin in preventing coronary artery reocclusion after thrombolysis
127. Clopidogrel is more effective than aspirin as adjuvant treatment to prevent reocclusion after thrombolysis
128. Importance of platelets in experimental venous thrombosis in the rat
129. Potentiating effect of clopidogrel and SR 46349, a novel 5-HT2 antagonist, on strepto-kinase-induced thrombolysis in the rabbit
130. Effect of clopidogrel on thrombin generation in platelet-rich plasma in the rat
131. 2T purinoceptor antagonists: Definition of the role of ADP in arterial thrombosis
132. Prevention of arterial thrombosis by intravenously administered platelet P2T recetor antagonist AR-C69931MX in a canine model
133. 1 receptor deficient mice